Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Mortality
Hospitalization
Serious outcomes
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Nigella Sativa  COVID-19 treatment studies for Nigella Sativa  C19 studies: Nigella Sativa  Nigella Sativa   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Outcomes in COVID-19 nigella sativa studies
00.250.50.7511.251.51.752+Ashraf (RCT)82%0.18 [0.04-0.80]death2/15711/156CT​1Improvement, RR [CI]TreatmentControlAl-Haidari (RCT)96%0.04 [0.00-0.70]death0/16014/259Koshak (RCT)75%0.25 [0.03-2.22]hosp.1/914/92Tau​2 = 0.00; I​2 = 0.0%Early treatment84%0.16 [0.05-0.48]3/40829/50784% improvementAl-Haidari62%0.38 [0.31-0.46]symp. case68/188180/188Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP62%0.38 [0.31-0.46]68/188180/18862% improvementAll studies67%0.33 [0.21-0.52]71/596209/69567% improvement4 nigella sativa COVID-19 studiesc19ns.com Sep 17, 20211 CT: study uses combined treatmentTau​2 = 0.06; I​2 = 10.1%; Z = 4.72Effect extraction pre-specifiedFavors nigella sativaFavors control 00.250.50.7511.251.51.752+Ashraf (RCT)82%0.18 [0.04-0.80]2/15711/156CT​1Improvement, RR [CI]TreatmentControlAl-Haidari (RCT)96%0.04 [0.00-0.70]0/16014/259Tau​2 = 0.00; I​2 = 0.0%Early treatment87%0.13 [0.04-0.49]2/31725/41587% improvementAll studies87%0.13 [0.04-0.49]2/31725/41587% improvement2 nigella sativa COVID-19 mortality resultsc19ns.com Sep 17, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 3.02Favors nigella sativaFavors control 00.250.50.7511.251.51.752+Koshak (RCT)75%0.25 [0.03-2.22]hosp.1/914/92Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment75%0.25 [0.03-2.22]1/914/9275% improvementAll studies75%0.25 [0.03-2.22]1/914/9275% improvement1 nigella sativa COVID-19 hospitalization resultc19ns.com Sep 17, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.24Favors nigella sativaFavors control 00.250.50.7511.251.51.752+Ashraf (RCT)82%0.18 [0.04-0.80]death2/15711/156CT​1Improvement, RR [CI]TreatmentControlAl-Haidari (RCT)96%0.04 [0.00-0.70]death0/16014/259Koshak (RCT)75%0.25 [0.03-2.22]hosp.1/914/92Tau​2 = 0.00; I​2 = 0.0%Early treatment84%0.16 [0.05-0.48]3/40829/50784% improvementAll studies84%0.16 [0.05-0.48]3/40829/50784% improvement3 nigella sativa COVID-19 serious outcomesc19ns.com Sep 17, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 3.23Effect extraction pre-specifiedFavors nigella sativaFavors control 00.250.50.7511.251.51.752+Ashraf (RCT)82%0.18 [0.12-0.27]107 (n)103 (n)CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment82%0.18 [0.12-0.27]0/1070/10382% improvementAll studies82%0.18 [0.12-0.27]0/1070/10382% improvement1 nigella sativa COVID-19 viral clearance resultc19ns.com Sep 17, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 8.68Favors nigella sativaFavors control 00.250.50.7511.251.51.752+Ashraf (RCT)82%0.18 [0.04-0.80]death2/15711/156CT​1Improvement, RR [CI]TreatmentControlAl-Haidari (RCT)96%0.04 [0.00-0.70]death0/16014/259Koshak (RCT)75%0.25 [0.03-2.22]hosp.1/914/92Tau​2 = 0.00; I​2 = 0.0%Early treatment84%0.16 [0.05-0.48]3/40829/50784% improvementAll studies84%0.16 [0.05-0.48]3/40829/50784% improvement3 nigella sativa COVID-19 Randomized Controlled Trialsc19ns.com Sep 17, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 3.23Effect extraction pre-specifiedFavors nigella sativaFavors control 00.250.50.7511.251.51.752+Ashraf (RCT)82%0.18 [0.04-0.80]2/15711/156CT​1Improvement, RR [CI]TreatmentControlAl-Haidari (RCT)96%0.04 [0.00-0.70]0/16014/259Tau​2 = 0.00; I​2 = 0.0%Early treatment87%0.13 [0.04-0.49]2/31725/41587% improvementAll studies87%0.13 [0.04-0.49]2/31725/41587% improvement2 nigella sativa COVID-19 RCT mortality resultsc19ns.com Sep 17, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 3.02Favors nigella sativaFavors control 00.250.50.7511.251.51.752+Al-Haidari (RCT)96%0.04 [0.00-0.70]death0/16014/259Improvement, RR [CI]TreatmentControlKoshak (RCT)75%0.25 [0.03-2.22]hosp.1/914/92Tau​2 = 0.00; I​2 = 0.0%Early treatment87%0.13 [0.02-0.72]1/25118/35187% improvementAl-Haidari62%0.38 [0.31-0.46]symp. case68/188180/188Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP62%0.38 [0.31-0.46]68/188180/18862% improvementAll studies69%0.31 [0.15-0.67]69/439198/53969% improvement3 nigella sativa COVID-19 peer reviewed trialsc19ns.com Sep 17, 2021Tau​2 = 0.17; I​2 = 18.1%; Z = 3.01Effect extraction pre-specifiedFavors nigella sativaFavors control 00.250.50.7511.251.51.752+Ashraf (RCT)82%0.18 [0.04-0.80]death2/15711/156CT​1Improvement, RR [CI]TreatmentControlAshraf (RCT)67%0.33 [0.01-7.99]death0/1071/103CT​1Ashraf (RCT)79%0.21 [0.05-0.92]death2/5010/53CT​1Ashraf (RCT)84%0.16 [0.11-0.24]no recov.107 (n)103 (n)CT​1Ashraf (RCT)75%0.25 [0.15-0.41]no recov.50 (n)53 (n)CT​1Ashraf (RCT)82%0.18 [0.12-0.27]viral+107 (n)103 (n)CT​1Ashraf (RCT)77%0.23 [0.14-0.38]viral+50 (n)53 (n)CT​1Al-Haidari (RCT)96%0.04 [0.00-0.70]death0/16014/259Al-Haidari (RCT)93%0.07 [0.02-0.30]severe case2/16044/259Koshak (RCT)75%0.25 [0.03-2.22]hosp.1/914/92Koshak (RCT)43%0.57 [0.42-0.78]no recov.34/9160/92Al-Haidari62%0.38 [0.31-0.46]symp. case68/188180/188nigella sativa COVID-19 outcomesc19ns.com Sep 17, 2021Favors nigella sativaFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit